Key facts
- It has raised $1.1M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Centro de Innovación y Emprendimientos, Cites Startups.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for RadBio
- ·The full record, as it builds
Funding rounds
No funding rounds for RadBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RadBio
Developer of a therapeutic platform targeting fibrotic diseases and solid tumors with unmet medical needs. The company offers an Fc-fusion protein that neutralizes excess TGF-β without blocking its signaling cascade, enabling potential treatment for various fibrotic conditions and cancers.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2018
- Employees
- 7
- Website
- radbiopharm.com/
- Ownership
- Privately Held (backing)
RadBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RadBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RadBio in its N-PORT filings yet. We sweep new filings monthly.